Who will dominate the cholesterol market? Amgen or Sanofi?

Source: on May 28, 2015, two companies, Amgen and Sanofi, have changed the pharmaceutical market by virtue of their own new cholesterol lowering therapy The new drugs they produce are PCSK9 protein inhibitors, which can target specific proteins and weaken their ability to maintain "bad" LDL levels in the blood The two companies compete with each other in drug research and development, taking the lead At present, repatha, a cholesterol lowering drug developed by Amgen, is undergoing FDA approval In November, the drug's BLA was accepted; in April, the FDA Committee's approval of repatha was held Sappino's cholesterol lowering drug, praluent, was developed with partner regeneron pharmaceuticals The drug is expected to change the cholesterol lowering drug market On January 9, praluent obtained the approval of biological preparations and the rapid approval of FDA Saifino has spent $67.4 million to ensure that the entire approval process is carried out quickly FDA will announce the approval result of saifino praluent on July 24 and the approval result of Enjin repatha on August 27 An expert meeting will also be held on June 9 and 10 to jointly consider the two drugs On March 15, data from two drug evaluation trials were published in the New England Journal of medicine On the same day, the two companies also presented research results at the annual meeting of the American Heart Association, demonstrating that PCSK9 can reduce cardiovascular side effects by 50% These experimental data add to the confidence of corporate investors As soon as the final results of the two drugs were released, Amgen's shares rose 5.7% on March 16, safino 3.3% and regeneron 5.2% What's different about these two drugs? One of the characteristics of the two drugs is the post marketing dose Amgen may win in terms of dosage One of its injection contains 140mg, once every two weeks; the other contains 420mg, once a month The drug developed by saifino and regenron only has two doses of 75mg and 150mg, once every two weeks This kind of drugs can be said to have triggered a fierce battle for a larger market The dosage form of Amgen once a month can provide more convenience for patients, and the strategic price reduction of 75 mg injection produced by saifino and regeneron has the same advantage How does safino win in the competition? Dr Jennifer Robinson is an epidemiologist at the University of Iowa and head of clinical trials at praluent He said: saifino and regeneron can reduce the drug price and put themselves in a favorable position This is crucial, and companies can reap huge benefits from it, as the heads of the medical system are constantly asking drug manufacturers to lower the price of new drugs.